Showing results (11-20 of 19) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Frontiers in Pediatrics|November 1, 2021
Characterization of Plasma Protein Alterations in Pregnant and Postpartum Individuals Living With HIV to Support Physiologically-Based Pharmacokinetic Model DevelopmentSherry Zhao, Mary Gockenbach, Manuela Grimstein, et al.CPT: Pharmacometrics & Systems Pharmacology|July 4, 2021
Anti-SARS-CoV-2 Repurposing Drug Database: Clinical Pharmacology ConsiderationsXinyuan Zhang, Yuching Yang, Manuela Grimstein, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 25, 2023
FDA Approval Summary: Pirtobrutinib for Relapsed or Refractory Mantle Cell LymphomaDeepti Telaraja, Yvette L Kasamon, Justin S Collazo, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 2024
FDA Approval Summary: Asciminib for Ph+ CML in Chronic Phase Treated with Two or More Tyrosine Kinase Inhibitors and for the T315I MutationGulsum E Pamuk, Edwin C Y Chow, Alexei C Ionan, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 14, 2024
FDA Approval Summary: Repotrectinib for Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung CancerMichael I Barbato, Diana Bradford, Yi Ren, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 21, 2024
US Food and Drug Administration Approval Summary: Elacestrant for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, ESR1-Mutated Advanced or Metastatic Breast CancerMirat Shah, Hima Lingam, Xin Gao, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 4, 2021
FDA Approval Summary: Capmatinib and Tepotinib for the Treatment of Metastatic NSCLC Harboring MET Exon 14 Skipping Mutations or AlterationsLuckson N Mathieu, Erin Larkins, Oladimeji Akinboro, et al.Molecular Pharmaceutics|September 30, 2024
PBBM Considerations for Base Models, Model Validation, and Application Steps: Workshop Summary ReportTycho Heimbach, Flora Musuamba Tshinanu, Kimberly Raines, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 11, 2025
US Food and Drug Administration Approval Summary: Ribociclib With an Aromatase Inhibitor in the Adjuvant Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Stage II and III High-Risk Early Breast Cancer Treatment SettingJennifer J Gao, Tatiana M Prowell, Haley Gittleman, et al.Pageof 2